
## Multi-Sigma

### Prediction Model Integration and Multi-Objective Optimization in Pharmaceutical Development Using Multi-Sigma™

# This case study showcases Aizoth's Multi-Sigma, leveraging its AI chain analysis and multi-objective optimization to balance drug activity (pIC50) and side effects for BACE inhibitors, potential Alzheimer's treatments

#### 1. Prediction of Drug Activity and Side Effects (Risk of Vascular Disorders)


Multi-Sigma's prediction functionality enables training of AI models using molecular descriptors and biological properties to capture their interrelationship.



#### 2. Factor Analysis of Key Influences on Drug Activity and Side Effects (Risk of Vascular Disorders)


Multi-Sigma's factor analysis allows the identification of molecular descriptors that contribute to drug activity and the risk of vascular disorders, respectively.

Molecular Descriptor Significant Impact on	1. ATS5m: +7.02% 2. ATS4m: +6.89%	
Molecular Descriptor Impact on the Risk of	1. Xp-4d: +5.88% 2. ATS2m: +5.77%	



#### 3. Optimization of Drug Activity and Side Effects (Risk of Vascular Disorders)

By combining Multi-Sigma's AI chain analysis and optimization functionalities, it's possible to propose combinations of molecular descriptors that maximize drug activity while minimizing the risk of vascular disorders.



condition optimization support, and contract research and development. Multi-Sigma<sup>™</sup> is a cloud-based AI software designed for research and development, significantly reducing experimental workload and enabling researchers to discover innovative solutions to realworld challenges with minimal experimental datasets.

https://aizoth.com/service/multi-sigma info@aizoth.com



200

© 2024 AIZOTH Inc. All rights reserved. AIZOTH and Multi-Sigma is trademarks of AIZOTH Inc. All other marks are trademarks or registered trademarks of their respective holders.

